Articles
12.04.2021
Benefits of early dialogue with HTA

Remap Consulting has significant expertise in guiding companies through both EUnetHTA / EMA Parallel...

Read more
Articles
31.03.2021
Recent changes to Italian P&R

Within the last few months, the significant changes proposed to the Italian pricing and reimbursemen...

Read more
Articles
29.03.2021
What is Relative Effectiveness Assessment

Relative Effectiveness Assessment (REA) is a type of assessment that evaluates the effectiveness of ...

Read more
Articles
25.03.2021
Subscription style payment model

To tackle antibiotic resistance, novel antibiotics are being reserved as later-line therapy for more...

Read more
Articles
15.03.2021
Identifying market access challenges

Interactive eLearning is a fantastic way of engaging with small to large scale audiences that can be...

Read more
Articles
01.03.2021
NRDL expansions

China has the second largest healthcare system in the world. However, this market has been challengi...

Read more
Articles
11.02.2021
EMA Human Medicines

Last month, EMA published its overview of key recommendations for 2020 on the authorisation and safe...

Read more
Articles
26.01.2021
Improving access to innovative medicine in the UK

Following Brexit, the Medicines and Healthcare Regularoty Agency (MHRA) has become the UK's sole bod...

Read more
Articles
20.01.2021
What is a Value Proposition

For an audience to properly understand the value of a drug, evidence needs to be put into context.

Read more
Articles
16.12.2020
New PMPRB guidelines in Canada

The Patented Medicine Prices Review Board (PMPRB) has a mandate to ensure that patented medicines ar...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.